Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTRAVENOUS DOLASETRON AND ONDANSETRON IN PREVENTION OF POSTOPERATIVENAUSEA AND VOMITING - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLEDSTUDY
Autore:
KORTTILA K; CLERGUE F; LEESER J; FEISS P; OLTHOFF D; PAYEURMICHEL C; WESSEL P; NAVE S; HAHNE W; BROWN R;
Indirizzi:
UNIV HELSINKI,DEPT OBSTET & GYNAECOL,HAARTMANINKATU 2 FIN-00290 HELSINKI FINLAND HOP TENON F-75970 PARIS FRANCE ONZE LIEVE VROUW HOSP AMSTERDAM NETHERLANDS HOP UNIV DUPUYTREN LIMOGES FRANCE KLIN ANAESTHESIOL LEIPZIG GERMANY HOP HASENRAIN MULHOUSE FRANCE CHU NANTES,HOP DIEU F-44035 NANTES 01 FRANCE ROCHE STRASBOURG FRANCE HOECHST MARION ROUSSEL KANSAS CITY MO 00000
Titolo Testata:
Acta anaesthesiologica Scandinavica
fascicolo: 7, volume: 41, anno: 1997,
pagine: 914 - 922
SICI:
0001-5172(1997)41:7<914:IDAOIP>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
GYNECOLOGICAL SURGERY; ANTIEMETIC EFFICACY; 5-HT3 ANTAGONISTS; DROPERIDOL; ANESTHESIA; CISPLATIN; MESILATE; MESYLATE;
Keywords:
EMESIS; INTRAVENOUS DOLASETRON MESILATE; INTRAVENOUS ONDANSETRON; POSTOPERATIVE NAUSEA AND VOMITING, PREVENTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
33
Recensione:
Indirizzi per estratti:
Citazione:
K. Korttila et al., "INTRAVENOUS DOLASETRON AND ONDANSETRON IN PREVENTION OF POSTOPERATIVENAUSEA AND VOMITING - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLEDSTUDY", Acta anaesthesiologica Scandinavica, 41(7), 1997, pp. 914-922

Abstract

Background: Intravenous dolasetron mesilate has shown efficacy in theprevention of postoperative nausea and vomiting (PONV) when administered as a single dose prior to emergence from anesthesia. This trial compared intravenous dolasetron and ondansetron for the prevention of PONV when administered at induction of anesthesia. Methods: This double-blind, placebo-controlled, multicenter trial randomized patients to one of four single IV treatments: placebo, 25 or 50 mg dolasetron, or 4 mg ondansetron, Efficacy was measured by complete response (0 emetic episodes and no rescue medication), nausea severity and patient satisfaction as measured on a visual analog scale (VAS), investigator's rating of nausea severity, and total response (complete response with no nausea [less than or equal to 5 mm VAS]). Results: 514 patients at 24 sites were evaluated for efficacy. The 50 mg dolasetron and 4 mg ondansetron doses were statistically equivalent, and superior to placebo, forall efficacy measures. Complete response rates were 49%, 51%, 71% and64% for placebo, 25 and 50 mg dolasetron, and ondansetron, respectively. Dolasetron 50 mg was statistically superior to 25 mg dolasetron for complete response, total response, VAS maximum nausea, time to firstemetic episode, and patient satisfaction. The majority of adverse events were of mild-to-moderate intensity. Headache was the most frequently reported treatment-related adverse event with a 3%-5% incidence across treatments. Conclusion: When given at induction of anesthesia, 50 mg intravenous dolasetron is equivalent to 4 mg ondansetron and superior to 25 mg dolasetron anal placebo for the prevention of PONV. All treatments were safely administered and well tolerated.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 13:41:55